Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.
Bayer is pushing forward with a new heart-failure treatment that could eventually contend with Novartis' blockbuster-in-waiting Entresto, mapping out a wide Phase III program for its oral drug.
Bristol-Myers Squibb has landed the rights to buy out Lexington, MA-based Promedior, paying $150 million upfront and committing a total of $1.25 billion to the deal--if the biotech's fibrosis drug comes through in Phase II studies.
After remaking its pipeline to fit one of the hottest fashions in biotech and engineering a classic $70 million crossover round, South San Francisco-based CytomX is taking the inevitable next step with a $100 million IPO filing.
Amicus Therapeutics has stepped in to snap up the late-stage rare disease biotech Scioderm, beefing up its orphan drug pipeline in exchange for $229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.
Now that Amgen and the Regeneron/Sanofi team have scored pioneering approvals of two leading PCSK9 therapies, the race is already on to top the leaders with a new wave of even better drugs that can slash levels of bad cholesterol more efficiently. And Alnylam, alongside its partners at The Medicines Company, has staked out a claim to an RNAi treatment that could beat them all--some 5 years down the road.
Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.
A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, a stem cell researcher who went from being featured on the front page of the New York Times to fending off accusations of misconduct.
The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. The FDA's suggested solution: Take the generic name and add four random letters to make it a unique identifier.
There are a lot of reasons why oncologists aren't exactly brimming with excitement at the idea of getting their hands on Eli Lilly's lung cancer drug necitumumab.
Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry.
Amgen scored the big win for its PCSK9 drug Repatha (evolocumab). The FDA announced Thursday afternoon that it has given Amgen a green light on marketing the PCSK9 cholesterol drug, opening the door to what will likely prove a blockbuster market.
Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.
Amgen is likely to start today off with a case of bubbly chilling in the company cafeteria. The FDA has reached its deadline on a marketing decision for the cholesterol drug Repatha (evolocumab), which most likely is on the verge of becoming a major rival to the newly approved Praluent (alirocumab), from Regeneron and Sanofi.
Ablynx has decided to retain full ownership in the U.S. and Europe of its Phase III-ready drug for the orphan blood disease acquired thrombotic thrombocytopenic purpura (TTP). A Phase III trial of caplacizumab is due to start soon, setting Ablynx on a path it expects to lead to a filing for conditional approval in Europe early in 2017.